{"id":"NCT01050530","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-12","primaryCompletion":"2012-02","completion":"2012-02","firstPosted":"2010-01-15","resultsPosted":"2014-01-31","lastUpdate":"2014-03-04"},"enrollment":162,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cirrhosis"],"interventions":[{"type":"DRUG","name":"OPC-41061","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"OPC-41061","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"OPC-41061 at 7.5 mg/day or placebo will be orally administered once daily for 7 days to cirrhosis patients with ascites despite having received treatment with conventional diuretics and the change in body weight from baseline at the time of the final administration will be compared between the two groups.","primaryOutcome":{"measure":"Body ï½—eight","timeFrame":"Baseline, Day 7 or at the discontinued of treatment","effectByArm":[{"arm":"OPC-41061","deltaMin":-1.95,"sd":1.77},{"arm":"Placebo","deltaMin":-0.44,"sd":1.93}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":20},"locations":{"siteCount":8,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":82},"commonTop":["Constipation","Thirst","Diarrhoea","Pyrexia","Renal Impairment"]}}